Chikungunya vaccine

Last updated

Chikungunya vaccine
Vaccine description
Target Chikungunya virus
Vaccine type Attenuated
Clinical data
Trade names Ixchiq, others
AHFS/Drugs.com Monograph
License data
Routes of
administration 		Intramuscular
ATC code
  • None
Legal status
Legal status
Identifiers
DrugBank

Chikungunya vaccines are vaccines intended to provide acquired immunity against the chikungunya virus. [9] [11] As of 2025, two vaccines have been licensed in some countries. These are Ixchiq, a live attenuated vaccine from Valneva, and Vimkunya manufactured by Bavarian Nordic which utilises virus-like particle technology. [16] [17] [12] [14]

Contents

The most commonly reported side effects of Ixchiq include tenderness at the injection site, as well as headache, fatigue, muscle pain, joint pain, fever, and nausea. [17] However the license for Ixchiq has been suspended or restricted in some countries due to the risk of severe side effects, particularly in older people. [18] [19]

Medical uses

The chikungunya vaccine is indicated for the prevention of disease caused by chikungunya virus. [8] [10]

History

In November 2023, the US Food and Drug Administration (FDA) granted the application for the chikungunya vaccine with fast track, breakthrough therapy, and priority review designations. [17] The vaccine, Ixchiq, was licensed to Valneva Austria GmbH. [17] [20] It contains the live attenuated chikungunya virus (CHIKV) Δ5nsP3 strain of the ECSA/IOL genotype. [12]

Ixchiq was authorized for medical use in the European Union in June 2024. [12] [13] A second vaccine, Vimkunya, manufactured by Bavarian Nordic, was authorized for medical use in the European Union in February 2025. [14] [15]

References

  1. ↑ "Register Of Innovative Drugs [Updated: 2024-07-04]". Health Canada . 4 July 2024. Retrieved 15 July 2024.
  2. ↑ "Ixchiq Product information". Health Canada . 20 June 2024. Archived from the original on 15 July 2024. Retrieved 15 July 2024.
  3. ↑ "Summary Basis of Decision for Ixchiq". Drug and Health Products Portal. 1 September 2012. Retrieved 17 December 2024.
  4. ↑ "Regulatory Decision Summary for Ixchiq". Drug and Health Products Portal. 20 June 2024. Archived from the original on 7 December 2024. Retrieved 27 December 2024.
  5. ↑ "Ixchiq Chikungunya vaccine: temporary suspension in people aged 65 years or older". GOV.UK. 18 June 2025. Archived from the original on 24 June 2025. Retrieved 28 July 2025.
  6. ↑ "Ixchiq vaccine approved to protect adults against Chikungunya". GOV.UK (Press release). 4 February 2025. Retrieved 28 September 2025.
  7. ↑ "News". Bavarian Nordic Receives Marketing Authorization for Chikungunya Vaccine for Persons Aged 12 and Older in the United Kingdom (Press release). 2 May 2025. Retrieved 28 September 2025.
  8. 1 2 "Ixchiq- chikungunya vaccine, live-attenuated injection, powder, lyophilized, for solution". DailyMed. 9 November 2023. Retrieved 2 April 2025.
  9. 1 2 "Ixchiq". U.S. Food and Drug Administration. 9 November 2023. Archived from the original on 9 November 2023. Retrieved 10 November 2023.PD-icon.svg This article incorporates text from this source, which is in the public domain .
  10. 1 2 "Vimkunya- chikungunya vaccine, recombinant injection, suspension". DailyMed. 18 February 2025. Retrieved 2 April 2025.
  11. 1 2 "Vimkunya". U.S. Food and Drug Administration (FDA). 1 October 2024. Archived from the original on 4 March 2025. Retrieved 3 March 2025.
  12. 1 2 3 4 "Ixchiq EPAR". European Medicines Agency . 30 May 2024. Archived from the original on 1 June 2024. Retrieved 1 June 2024. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  13. 1 2 "Ixchiq PI". Union Register of medicinal products. 28 June 2024. Retrieved 28 September 2025.
  14. 1 2 3 "Vimkunya EPAR". European Medicines Agency . 30 January 2025. Archived from the original on 16 February 2025. Retrieved 16 February 2025. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  15. 1 2 "Vimkunya PI". Union Register of medicinal products. 28 February 2025. Retrieved 4 March 2025.
  16. ↑ "NaTHNaC - Chikungunya". National Travel Health Network and Centre. 14 April 2025. Retrieved 12 November 2025.
  17. 1 2 3 4 "FDA Approves First Vaccine to Prevent Disease Caused by Chikungunya Virus". U.S. Food and Drug Administration (FDA) (Press release). 9 November 2023. Archived from the original on 9 November 2023. Retrieved 10 November 2023.
  18. ↑ CDC (22 August 2025). "Chikungunya Vaccine Information for Healthcare Providers". Chikungunya Virus. Retrieved 12 November 2025. As of Friday, August 22, 2025, FDA suspended the U.S. license for IXCHIQ, the live-attenuated chikungunya vaccine.
  19. ↑ "IXCHIQ Chikungunya vaccine: temporary suspension in people aged 65 years or older". GOV.UK. 18 June 2025. Retrieved 12 November 2025. The Commission on Human Medicines (CHM) has temporarily restricted use of the IXCHIQ Chikungunya vaccine in people aged 65 years and over following very rare fatal reactions reported globally.
  20. ↑ Malhi S (10 November 2023). "FDA approves first vaccine against mosquito-borne virus chikungunya". The Washington Post . Archived from the original on 11 November 2023. Retrieved 13 November 2023.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.